A 12-week treatment for eosinophilic esophagitis (EoE) in patients 11 years of age and older. EOHILIA has not been shown to be safe and effective for longer than 12 weeks.1

Illustration of esophageal inflammation

FIRST AND ONLY FDA-APPROVED ORAL TREATMENT FOR EoE1

DESIGNED FOR EoE.

Inflammation relief where it matters.

The oral bioavailability in healthy subjects is ~14% under fasting state. Systemic effects may occur.

EOHILIA™ Animation Video Thumbnail

EOHILIA is an oral budesonide suspension designed specifically for EoE. Relief was defined as reduction in eosinophils in the esophagus and improvement in dysphagia symptoms in two 12-week clinical trials. Systemic effects may occur.1

See EOHILIA in action
Clinical program background image

The efficacy and safety profile of EOHILIA was evaluated in one of the

LARGEST CLINICAL PROGRAMS

of patients with EoE in the U.S.1

Study designs overview icon

Histological remission and dysphagia symptom responses with EOHILIA were studied in two 12-week clinical trials that included 410 patients 11-56 years of age with EoE.1

See the efficacy data
Safety overview icon

The safety profile of EOHILIA was evaluated in 410 patients with EoE in two 12-week clinical trials.1

View the safety profile

Explore a

BROAD RANGE

of patient types

Take a closer look at different patient types to see if they are similar to your patients with EoE.

Explore patient profiles
Image of EOHILIA™ (budesonide oral suspension) box and stick pack

RELIABLE

DOSING*

for on-the-go use

EOHILIA comes in premixed, single-dose stick packs (2 mg twice daily for 12 weeks).1

*When taken as recommended in the Prescribing Information.

See dosing and administration
Resources background image

RESOURCES

at your fingertips

Help your patients navigate their treatment journey at every step. Get resources designed to inform and support.

Go to savings + support Go to resources
Images of downloadable & printable resources for EOHILIA™ (budesonide oral suspension)

Reference:

  1. EOHILIA (budesonide oral suspension) Prescribing Information. Takeda Pharmaceuticals, Inc. 

VIDEO TRANSCRIPT

While eosinophilic esophagitis (EoE) symptoms are unique in each patient, the underlying cause is esophageal inflammation, due to an increase in eosinophils in the esophagus.

That’s why it’s important to treat inflammation where it occurs.

EOHILIA (budesonide oral suspension) is a corticosteroid indicated for 12 weeks of treatment in patients 11 years and older with EoE. EOHILIA has not been shown to be safe and effective for longer than 12 weeks. EOHILIA is contraindicated for patients with hypersensitivity to budesonide. Serious hypersensitivity reactions, including anaphylaxis, have occurred with oral budesonide products. Please continue watching until the end of the video for full Important Safety Information.

EOHILIA is specifically designed for EoE.

It is the first and only oral 12-week, FDA-approved treatment.

Indicated for people with EoE 11 years and older.

EOHILIA is designed with a viscosity that can change. At rest, EOHILIA is highly viscous. Upon shaking, it gets more fluid; and then regains viscosity to flow slower.

The ability to go from low to high viscosity is known as thixotropy.

This physical property creates a novel budesonide formulation.

EOHILIA is designed to fit into patients’ pockets and their daily routines, with a twice-daily 12-week dosing regimen.

It is ready for on-the-go use in pre-prepared, single-dose stick packs with no mixing, measuring, or refrigeration required.

Remind your patients that EOHILIA should be taken as prescribed:

2 mg twice daily, once in the morning and once in the evening, for 12 weeks.

EOHILIA. Designed for EoE. Treat inflammation where it occurs.